Publications of Michael W. Sereda
All genres
Journal Article (52)
1.
Journal Article
16, pp. 616 - 640 (2024)
Targeting PI3K/Akt/mTOR signaling in rodent models of PMP22 gene-dosage diseases. Embo Molecular Medicine 2.
Journal Article
35 (12), pp. 2136 - 2152.e9 (2023)
Adipo-glial signaling mediates metabolic adaptation in peripheral nerve regeneration. Cell Metabolism 3.
Journal Article
33 (10), pp. 665 - 667 (2022)
Location matters: hexokinase 1 in glucose metabolism and inflammation. Trends in Endocrinology & Metabolism 4.
Journal Article
8 (37), eabo7639 (2022)
Ketogenic diet uncovers differential metabolic plasticity of brain cells. Science Advances 5.
Journal Article
24, pp. 47 - 60 (2021)
Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis. Nature Neuroscience 6.
Journal Article
98 (10), pp. 1933 - 1952 (2020)
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats. Journal of Neuroscience Research 7.
Journal Article
27 (8), pp. 1390 - 1396 (2020)
Pregnancy outcome in Charcot–Marie–Tooth disease: results of the CMT‐NET cohort study in Germany. European Journal of Neurology 8.
Journal Article
9, e51406 (2020)
Proteome profile of peripheral myelin in healthy mice and in a neuropathy model. eLife 9.
Journal Article
39 (28), pp. 5606 - 5626 (2019)
Myelinating glia-specific deletion of Fbxo7 in mice triggers axonal degeneration in the central nervous system together with peripheral neuropathy. The Journal of Neuroscience 10.
Journal Article
10, 1467 (2019)
NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies. Nature Communications 11.
Journal Article
14 (1), e0209752 (2019)
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PLoS One 12.
Journal Article
9, 3025 (2018)
Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nature Communications 13.
Journal Article
88 (11), pp. 941 - 952 (2017)
Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. Journal of Neurology, Neurosurgery & Psychiatry 14.
Journal Article
6, e23332 (2017)
Peroxisomal dysfunctions cause lysosomal storage and axonal Kv1 channel redistribution in peripheral neuropathy. eLife 15.
Journal Article
8, 17 (2017)
Rho kinase inhibition with Fasudil in SOD1(G93A) mouse model of Amyotrophic Lateral Sclerosis - symptomatic treatment potential after diesease onset. Frontiers in Pharmacology 16.
Journal Article
95 (11), pp. 145 - 157 (2016)
Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiology of Disease 17.
Journal Article
19 (8), pp. 1050 - 1059 (2016)
Zeb2 is essential for Schwann cell differentiation, myelination and nerve repair. Nature Neuroscience 18.
Journal Article
18 (5), pp. 443 - 451 (2016)
The role of combined SNV and CNV burden in patients with distal symmetric polyneuropathy. Genetics in Medicine 19.
Journal Article
64 (1), pp. 155 - 174 (2016)
Proteolipid protein modulates preservation of peripheral axons and premature death when myelin protein zero is lacking. Glia 20.
Journal Article
2 (8), pp. 787 - 796 (2015)
Curcumin therapy in a Plp1 transgenic mouse model of Pelizaeus-Merzbacher disease. Annals of Clinical and Translational Neurology